Fukumoto, Kenichi

Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine

Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionTryptophan and brain disorders

Cited by 252

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 R ,6 R )-hydroxynorketamine

Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 188

The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN

Fukumoto, K., Iijima, M., & Chaki, S. (2016) · Neuropsychopharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 174

BDNF Release and Signaling Are Required for the Antidepressant Actions of GLYX-13

Kato, T., Fogaça, M. V., Deyama, S., Li, X.-Y., Fukumoto, K., & Duman, R. S. (2018) · Molecular Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 88

N-Methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects

Fogaça, M. V., Fukumoto, K., Franklin, T., Liu, R.-J., Duman, C. H., Vitolo, O. V., & Duman, R. S. (2019) · Neuropsychopharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 82